Volume 94 Issue 49 | p. 19 | Concentrates
Issue Date: December 19, 2016

Purdue licenses Exicure drug

Department: Business
Keywords: nucleic acids, Purdue, Exicure, oligonucleotides

Purdue Pharma has formed a pact with Exicure, a biotech firm developing “spherical nucleic acid” technology, which facilitates intracellular delivery of nucleic acids by tethering them to the surface of a nanoparticle. In exchange for an undisclosed payment and equity investment, Exicure will grant Purdue rights to its lead compound, AST-005, a topically applied treatment for psoriasis that has completed a Phase I study. Exicure is based on technology developed in the labs of Northwestern University chemist Chad Mirkin.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment